Treatment of hemangioma by embolizatio

Phase 3

• Conditions: Giant liver hemangioma.; Hemangioma; D18.0

• Registration Number: IRCT20191105045343N1
• Lead Sponsor: Shahed University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

Patients with giant hemangioma diagnosed by the relevant specialist
Patients with clinical signs of hemangioma enlargement

Exclusion Criteria

No Patient's consent
Patients with INR> 1.5

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The size of liver hemangioma lesions. Timepoint: Before, immediately after the intervention, one, three, six months after the intervention. Method of measurement: Lesion size by ultrasound, CT scan, MRI.;Liver enzymes. Timepoint: Before, immediately after the intervention, one, three, six months after the intervention. Method of measurement: Liver enzymes in the blood with a special kit.;The amount of pain. Timepoint: Before, immediately after the intervention, one, three, six months after the intervention. Method of measurement: Wong-baker criteria.